

![]() |
Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease |
|
Authors | ![]() | |
Published in | Annals of the rheumatic diseases. 2018, vol. 77, no. 6, p. 840-847 | |
Abstract | Adult-onset Still's disease (AOSD) is a rare systemic autoinflammatory disease; its management is largely empirical. This is the first clinical study to determine if interleukin (IL)-18 inhibition, using the recombinant human IL-18 binding protein, tadekinig alfa, is a therapeutic option in AOSD. | |
Identifiers | PMID: 29472362 | |
Full text | ||
Structures | ||
Research group | Mécanisme de l'inflammation articulaire (44) | |
Citation (ISO format) | GABAY, Cem et al. Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease. In: Annals of the Rheumatic Diseases, 2018, vol. 77, n° 6, p. 840-847. doi: 10.1136/annrheumdis-2017-212608 https://archive-ouverte.unige.ch/unige:110671 |